C07K 2319/33
Fusions for targeting to specific cell types
Official title: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
C07K2319/33 (Fusions for targeting to specific cell types) appears on 2,334 US grants and 4,539 published applications in this corpus.
Search patents in C07K- Granted patents
- 2,334
- Published applications
- 4,539
- Assignees
- 1,482
- Inventors
- 7,148
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 5 | 0 |
| 1991 | 2 | 0 |
| 1992 | 10 | 0 |
| 1993 | 13 | 0 |
| 1994 | 9 | 0 |
| 1995 | 9 | 0 |
| 1996 | 10 | 0 |
| 1997 | 8 | 0 |
| 1998 | 20 | 0 |
| 1999 | 14 | 0 |
| 2000 | 11 | 0 |
| 2001 | 5 | 1 |
| 2002 | 4 | 3 |
| 2003 | 2 | 12 |
| 2004 | 2 | 18 |
| 2005 | 2 | 15 |
| 2006 | 13 | 20 |
| 2007 | 2 | 18 |
| 2008 | 8 | 31 |
| 2009 | 8 | 40 |
| 2010 | 20 | 36 |
| 2011 | 13 | 65 |
| 2012 | 25 | 57 |
| 2013 | 31 | 73 |
| 2014 | 51 | 96 |
| 2015 | 64 | 120 |
| 2016 | 71 | 181 |
| 2017 | 89 | 180 |
| 2018 | 97 | 241 |
| 2019 | 144 | 341 |
| 2020 | 182 | 420 |
| 2021 | 233 | 558 |
| 2022 | 233 | 552 |
| 2023 | 213 | 460 |
| 2024 | 267 | 446 |
| 2025 | 282 | 347 |
| 2026 | 158 | 208 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders29 Sep 2026US 12,747,277 B2AvenCell Europe GmbH
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Targeting of human interferon antagonists22 Sep 2026US 12,741,998 B2Centre Hospitalier Regional Universitaire De Montpellier
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Peptide tags for ligand induced degradation of fusion proteins15 Sep 2026US 12,735,463 B2Dana-Farber Cancer Institute, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308231 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308232 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308233 A1Regeneron Pharmaceuticals, Inc.
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Car-t cell compositions, methods of use thereof1 Oct 2026US 2026/0297160 A1Augusta University Research Institute, Inc.
Most cited
By later US patents
- Hybrid immunoglobulins817US 5,116,964 AGenentech, Inc. · 1992
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for targeting the vasculature of solid tumors254US 6,051,230 ABoard of Regents, The University of Texas System · 2000
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014